0

Handok

Company Profile

1

2

Mission

Vision

Values

3

2.01.0 3.0

2012Closed Joint Venture with SanofiInvested in 30% of Genexine Shares

2013Established Teva-Handok Joint Venture

2014Acquired Pharma Business of Pacific Pharma

2015Established Handok Kalos Medical

2016Invested in NB PostechAcquired Theravalues Corp., Japan

2019- Acquired Rezolute Inc.(US clinical stage biopharmaceutical company) with Genexine- Acquired of TRIGR Therapeutics (US company focused on the clinical development and commercialization)

4

Handok

Kalos Medical(Medical Device)

Theravalues(Japan/

Health Functional

Food)

Genexine(Biologics)

NB Postech(Medical Device)

Just-C(US/

Health

Functional

Drinks)

Teva-Handok(Specialty/

Generics)

Subsidiary Affiliated

Rezolute(US/Clinical-stage

Biopharmaceutial)

TRIGR

Therapeutics (US/NRDO*

Biopharmaceutial)

* NRDO(No Research Development Only)

5

As of April 2019

6

221 211 202229 240 248

23 40 40

4549

561810

20

4551 58

6173

70

3539 39

4039

44

3

39

4

2

4

41 10

CAGR 6.45%

7

8

Partnership

1954 ~ 2000 2001 ~ 2005 2006 ~ 2010 2013 ~2011 ~ 2012

9

Open

Innovation

Global Innovative

Drugs/ Biologics

Globalization of

IMD/FDC

Health

Functional

Food

Innovative

Medical Device

& Diagnostics

• Developing First-in-class, Best-in-

class drugs in cancer, diabetes,

rare diseases and

psycho/neurological diseases

− Long-acting growth hormone

(GX-H9) using Genexine’s

Hybrid Fc technology

− Co-development of pan-TRK

inhibitor with CMG Pharma

(research supported by National

OncoVenture)

• Research into topical patches using

TDDS(Transdermal Drug Delivery

System) technology

• Developing fixed-dose oral

combination of drug with different

dosing regimens using DRM (Dual

Release Micro-coating) technology

• Developing DENEXTM, medical

device for treating refractory

hypertension (Handok Kalos

Medical)

• Developing ex-vivo diagnostic

with NB Postech

Product Development

Research Center

Handok Kalos Medical

(R&D Spin-off for

Medical Device)

• Association with prominent research institutes in Korea & abroad based on Open Innovation strategy

• Developing functional ingredients for

health care of the future

• Developing health functional food with

Theracurmin

- Ready Q Drink/Chew, Theracurmin

powder

Handok R&D

Handok New Drug &

Biopharmaceutial

Research Center

10

■ Biologics ■ small molecules ■ Medical Device

Therapeutic

AreaProject Category Indication

Resear

ch

Pre-

ClinicalP1 P2 P3 Remarks

OrphanHL2356

(GX-H9)Bio-better

Growth Hormone

Deficiency in

Adults

Growth Hormone

Deficiency in

Pediatrics

Oncology HL5101 NCE Cancer

Ophthalmic HL3501 NCE Glaucoma

Diabetes

/Endo

HL550 IMDDiabetes +

dyslipidemia

HD-

C715NCE Diabetes

CV DENEXMedical

Devices

Refractory

Hypertension

CV/

InfectionRST Kit Diagnostics CV/Infection

• Genexine partnered

• CMG Pharma

partnered

• CE mark (2016)

13

As a global total healthcare company in Korea,

Handok will become The Health Innovator

Content

1. Overview

2. Technology

3. Products

4. Progress

5. Plan

Nanosurface Biosciences POSTECH Inc.

14

Date of Foundation : Feb. 8, 2008

Capital : 1,452 M KRW

Headquarter : 4th Floor, Biotech Center, POSTECH

Key Business : Surface Coating for Bioanalysis and

Production of Kits for Medical Diagnostics

Founder and CEO : Joon Won Park (朴準遠)

Education : Sogang Univ. / KAIST / CALTECH

Experience : Director, Bionanotech Center, POSTECH

Dean of Science, Head of Chemistry, POSTECH

Head, BK21 plus program

Director, POSTECH-Catholic Biomedical Engineering Institute

CEO, NB POSTECH Inc.

1. Overview (I)

15

1. Overview (II) - Chronology

Research

Seed

Germination

Growth

2000 : Surface coating for microarrays (supported

by POSCO and POSTECH)

2003 : Patent applications in US, EU, Japan, etc.

2008 : Foundation of NB POSTECH Inc.

2008 : Technology transfer from POSTECH

2009 : Foundation of Nanogea in US

2010 : 1B KRW from Handok

2014 : Diversification of products (glass slides, rod,

wafer, membrane, etc.)

2016: 9B KRW from Handok

2017: Pilot production facility in Anyang

2018: KGMP, ISO 13485

2020: Sales in EU and Korea

16

2. Technology (I) – NanoCones

- Proper lateral spacing for the biomolecules of YOUR interest

3 ~ 10 nmThe spacing can be adjusted based on your needs.

• DNA, RNA, PNA, LNA

• Protein

• Aptamer

• Carbohydrate

• Others

A recent review: J. Mater. Chem. B,

5153 (2015)

17

2. Technology (II) – Flexibility

Surface coating with size-controlled NanoCones

Spacing between functionalities is controlled precisely up to 10nm

Lateral spacing

3 nm 10 nm

2nd generation

6 nm

4th generation3rd generation

18

19

2. Technology – Patents

AFM

Applica

tions

Master Patent: Size-Controlled Macromolecule

US

US, EP, Canada, Australia, China, Japan, Russia, India,

Korea, Germany, Switzerland, France, United kingdom

Solid substrates comprising array of dendrons and methods for using the same

Bimolecular Interaction Using AFM US, EP, Japan, Korea, China

Solid substrates with surface bound molecules and methods for producing and using the same (single molecule picking)

US, EP

* Patents were issued in countries in red.

Polynucleotide synthesis on a modified surface ( on-chip polymerization)

Atomic force microscope as an analyzing tool for biochip

US

US, EP, Japan

Additional IPs being added, expanded, and filed as patents

3. Products

Slides

Protein Microarray

AFM probes

9-Acid coated slides27-Acid coated slides

Kinase microarrayCytokine microarray

NanoCones coated AFM probe

Silicon Wafers NanoCones coated wafers

Rod NanoCones coated rod

20

21

NanoConeTM Technology

Slides

AFM probes

Silicon wafers

Rods

New membranes

Enhanced Performance

Low Coefficient of Variation

Immobilization of

Antibodies through Covalent

Bond

Ideal for Strip Sensors for Diagnostics

3. NanoCone-treated Membranes

A NC membrane utilizes electrostatic attraction to immobilize antibodies.The approach is convenient and effective, but suffers from relativelyhigh variation of the result.

Example: Rapid Flow Assay Kit

Nitrocellulose Membrane

Format of a Strip Sensor

22

RST- Structure of Rapid Screening Test Kit

23

Location of Pilot Production Facility

24

The Facility is located at 3rd Floor.

25

Floor Plan of the Facility

26

Future Plan

휴

• Sales of rapid flow kits for myocardial infarction, influenza, drug abuse

• Ultrasensitive protein microarrays for research and diagnostics

• Extending towards U-Healthcare products by implementing the high accuracy into electronic devices such as mobile phones

• Quantification of various biomarkers of low abundance with AFM – Protein and miRNA analyses from a single cell, liquid biopsy, Alzheimer diseases, human assisted reproduction, etc.

27